A number of approved drugs, including copyright and Semaglutide, are part of the GLP-1 receptor agonist category . Essentially , these therapies are designed to mimicking the body's own hormones that control blood sugar and encourage slimming. While copyright is a specific formulation for diabet

Patients struggling with obesity are often faced with limited and sometimes ineffective treatment options. However, a groundbreaking new medication, Semaglutide, is rapidly changing the landscape of weight loss. Approved by regulatory bodies for chronic weight management, Semaglutide works as a